> top > docs > PubMed:32285930 > annotations

PubMed:32285930 JSONTXT

Annnotations TAB JSON ListView MergeView

PubMed_ArguminSci

Id Subject Object Predicate Lexical cue
T1 130-233 DRI_Background denotes Hydroxychloroquine (HCQ) is a promising candidate for Coronavirus Disease of 2019 (COVID-19) treatment.
T2 234-271 DRI_Approach denotes The optimal dosing of HCQ is unknown.
T3 272-434 DRI_Challenge denotes Our goal was to integrate historic and emerging pharmacological and toxicity data to understand safe and efficacious HCQ dosing strategies for COVID-19 treatment.
T4 435-859 DRI_Outcome denotes The data sources included were 1) longitudinal clinical, pharmacokinetic, and virologic data from patients with severe acute respiratory syndrome-2 (SARS-CoV-2) infection who received HCQ with or without azithromycin (n=116), 2) in vitro viral replication data and SARS-CoV-2 viral load inhibition by HCQ, 3) a population pharmacokinetic model of HCQ and 4) a model relating chloroquine pharmacokinetics to QTc prolongation.
T5 860-1009 DRI_Challenge denotes A mechanistic PK/virologic/QTc model for HCQ was developed and externally validated to predict SARS-CoV-2 rate of viral decline and QTc prolongation.
T6 1087-1408 DRI_Outcome denotes The extrapolated patient EC50 was 4.7 µM, comparable to the reported in vitro EC50 's. HCQ doses > 400 mg BID for ≥5 days were predicted to rapidly decrease viral loads, reduce the proportion of patients with detectable SARS-CoV-2 infection, and shorten treatment courses, compared to lower dose (≤400 mg daily) regimens.
T7 1409-1485 DRI_Background denotes However, HCQ doses >600 mg BID were also predicted to prolong QTc intervals.
T8 1486-1572 DRI_Approach denotes This prolongation may have clinical implications warranting further safety assessment.
T9 1573-1680 DRI_Background denotes Due to COVID-19's variable natural history, lower dose HCQ regimens may be indistinguishable from controls.
T10 1681-1761 DRI_Background denotes Evaluation of higher HCQ doses is needed to ensure adequate safety and efficacy.

LitCovid-OGER-BB

Id Subject Object Predicate Lexical cue
T1 11-29 CHEBI:5801 denotes hydroxychloroquine
T2 11-29 DG_20 denotes hydroxychloroquine
T3 11-29 CHEBI:5801 denotes hydroxychloroquine
T4 55-63 SP_7 denotes COVID-19
T5 112-116 CHEBI:23888 denotes drug
T6 112-116 CHEBI:23888 denotes drug
T7 130-148 CHEBI:5801 denotes Hydroxychloroquine
T8 130-148 DG_20 denotes Hydroxychloroquine
T9 130-148 CHEBI:5801 denotes Hydroxychloroquine
T10 184-195 NCBITaxon:11118 denotes Coronavirus
T11 213-221 SP_7 denotes COVID-19
T12 320-335 CHEBI:52217 denotes pharmacological
T13 320-335 CHEBI:52217 denotes pharmacological
T14 415-423 SP_7 denotes COVID-19
T15 492-507 CHEBI:52217 denotes pharmacokinetic
T16 492-507 CHEBI:52217 denotes pharmacokinetic
T17 560-571 UBERON:0001004 denotes respiratory
T18 584-594 SP_7 denotes SARS-CoV-2
T19 639-651 CHEBI:2955 denotes azithromycin
T20 639-651 CHEBI:2955 denotes azithromycin
T21 639-651 DG_6 denotes azithromycin
T22 673-678 NCBITaxon:10239 denotes viral
T23 673-690 GO:0006260 denotes viral replication
T24 700-710 SP_7 denotes SARS-CoV-2
T25 711-716 NCBITaxon:10239 denotes viral
T26 810-821 CHEBI:3638 denotes chloroquine
T27 810-821 CHEBI:3638 denotes chloroquine
T28 810-821 DG_10 denotes chloroquine
T29 955-965 SP_7 denotes SARS-CoV-2
T30 974-979 NCBITaxon:10239 denotes viral
T31 1010-1020 SP_7 denotes SARS-CoV-2
T32 1021-1026 NCBITaxon:10239 denotes viral
T33 1174-1177 CHEBI:17883 denotes HCQ
T34 1174-1177 CHEBI:17883 denotes HCQ
T35 1244-1249 NCBITaxon:10239 denotes viral
T36 1307-1317 SP_7 denotes SARS-CoV-2
T37 1580-1588 SP_7 denotes COVID-19

hydroxychloroquine

Id Subject Object Predicate Lexical cue hp_id
T1 1463-1484 Phenotype denotes prolong QTc intervals http://purl.obolibrary.org/obo/HP_0005184